Avid Bioservices Inc (CDMO)

[biopharm]

Trivia question regarding PS Targeting and how it is all leading to major Avid Bioservices contracts and more.....

What is the closest number of proteins related to ones immune system, that differ from a normal healthy person 18-40 ...vs 40-60 vs 60+ ? All vs the same individual groups for one with early EARLY stages of cancer before stage 1 vs stage 2 vs stage 3 vs stage 4 (does it change between types of cancer IN early stages vs late stages hmmm)

I guess before one answers one must know a good estimate for how many proteins are related to ones immune system so let's start there

100 proteins

250 proteins

500 proteins

1000 proteins

1500 proteins

2000 proteins

5000+ proteins

Now we realize how important biomarkers are and the list of proteins that do change require PS Targeting to realize which ones to pay attention to and which ones to monitor only

I never knew Merck had so many ties into so many things

____________


David Wallach

David Wallach did his M.Sc. and doctoral studies at the Department of Biological Chemistry, The Hebrew University of Jerusalem, Israel, and his postdoctoral training at the National Cancer Institute, Bethesda, Maryland, USA. He is currently a professor at the Weizmann Institute of Science, Rehovot, Israel.

His studies were the first to provide conclusive evidence that the â??type Iâ?? (anti-viral) and â??type IIâ?? (immune) interferons act through distinct mechanisms and have distinct patterns of effects.

Over the past 30 years, Prof. Wallach and his colleagues have been engaged in elucidating the mode of action of cytokines of the TNF family. They contributed to the isolating TNF, to the isolating and cloning the soluble and cells surface forms of the two TNF receptors and to the study of the shedding mechanisms of these receptors. His research group was of the first to decipher the extrinsic apoptotic cell-death pathway, to clone its major components (FADD/MORT1, caspase-8/MACH, and cFLIP/CASH) and to define their structural motifs (death domain, death-effector domain). They were also of the first to clone several of the signaling proteins that mediate effects of the TNF family on the NF-?B transcription factors. They continuously explore further the mechanisms of action of these signaling proteins and their physiological functions.
http://www.tnf2015.org/content/david-wallach

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=110833328

________


Functions of receptors of the TNF family are central to the pathology of various diseases. Since its inception, our research has been conducted with the support and collaboration of the Merck-Serono company and its Israeli subsidiary Interpharm, and has been aimed not only at acquiring basic knowledge, but also at applying this knowledge to the treatment of diseases to which members of the TNF family contribute. Part of the insights gained through this collaboration has already been applied to the treatment of chronic inflammatory diseases such as psoraisis, rheumotoid arthritis and Crohn's disease. By elucidating the intricacies of the signaling mechanisms activated by the TNF family we hope to form the basis for future development of drugs for other diseases to which this receptor family contributes.

https://www.weizmann.ac.il/Biomolecular_Sciences/Wallach/home